These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 16612192)

  • 1. What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update.
    Abbott C; Bustillo J
    Curr Opin Psychiatry; 2006 Mar; 19(2):135-9. PubMed ID: 16612192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton magnetic resonance spectroscopy of the human brain in schizophrenia.
    Deicken RF; Johnson C; Pegues M
    Rev Neurosci; 2000; 11(2-3):147-58. PubMed ID: 10718151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus.
    Yoo SY; Yeon S; Choi CH; Kang DH; Lee JM; Shin NY; Jung WH; Choi JS; Jang DP; Kwon JS
    Schizophr Res; 2009 Jun; 111(1-3):86-93. PubMed ID: 19406622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study.
    Ohrmann P; Siegmund A; Suslow T; Spitzberg K; Kersting A; Arolt V; Heindel W; Pfleiderer B
    Schizophr Res; 2005 Mar; 73(2-3):153-7. PubMed ID: 15653258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical antipsychotic drug treatment for 6 months restores N-acetylaspartate in left prefrontal cortex and left thalamus of first-episode patients with early onset schizophrenia: A magnetic resonance spectroscopy study.
    Gan JL; Cheng ZX; Duan HF; Yang JM; Zhu XQ; Gao CY
    Psychiatry Res; 2014 Jul; 223(1):23-7. PubMed ID: 24831926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
    Ohrmann P; Siegmund A; Suslow T; Pedersen A; Spitzberg K; Kersting A; Rothermundt M; Arolt V; Heindel W; Pfleiderer B
    J Psychiatr Res; 2007 Oct; 41(8):625-34. PubMed ID: 16949099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy.
    Bartha R; Williamson PC; Drost DJ; Malla A; Carr TJ; Cortese L; Canaran G; Rylett RJ; Neufeld RW
    Arch Gen Psychiatry; 1997 Oct; 54(10):959-65. PubMed ID: 9337777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy.
    Tandon N; Bolo NR; Sanghavi K; Mathew IT; Francis AN; Stanley JA; Keshavan MS
    Schizophr Res; 2013 Aug; 148(1-3):59-66. PubMed ID: 23791389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample.
    Bustillo JR; Jones T; Chen H; Lemke N; Abbott C; Qualls C; Stromberg S; Canive J; Gasparovic C
    Schizophr Bull; 2017 May; 43(3):611-619. PubMed ID: 27550776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.
    Natsubori T; Inoue H; Abe O; Takano Y; Iwashiro N; Aoki Y; Koike S; Yahata N; Katsura M; Gonoi W; Sasaki H; Takao H; Kasai K; Yamasue H
    Schizophr Bull; 2014 Sep; 40(5):1128-39. PubMed ID: 24023251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1 H-MR spectroscopy in ultra-high risk and first episode stages of schizophrenia.
    Uhl I; Mavrogiorgou P; Norra C; Forstreuter F; Scheel M; Witthaus H; Ozgürdal S; Gudlowski Y; Bohner G; Gallinat J; Klingebiel R; Heinz A; Juckel G
    J Psychiatr Res; 2011 Sep; 45(9):1135-9. PubMed ID: 21397254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T.
    Bustillo JR; Chen H; Jones T; Lemke N; Abbott C; Qualls C; Canive J; Gasparovic C
    JAMA Psychiatry; 2014 Mar; 71(3):265-72. PubMed ID: 24402128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS).
    Tayoshi S; Sumitani S; Taniguchi K; Shibuya-Tayoshi S; Numata S; Iga J; Nakataki M; Ueno S; Harada M; Ohmori T
    Schizophr Res; 2009 Mar; 108(1-3):69-77. PubMed ID: 19097753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1H-MRS at 4 tesla in minimally treated early schizophrenia.
    Bustillo JR; Rowland LM; Mullins P; Jung R; Chen H; Qualls C; Hammond R; Brooks WM; Lauriello J
    Mol Psychiatry; 2010 Jun; 15(6):629-36. PubMed ID: 19918243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect.
    Heimberg C; Komoroski RA; Lawson WB; Cardwell D; Karson CN
    Psychiatry Res; 1998 Aug; 83(2):105-15. PubMed ID: 9818736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients.
    Stanley JA; Williamson PC; Drost DJ; Rylett RJ; Carr TJ; Malla A; Thompson RT
    Schizophr Bull; 1996; 22(4):597-609. PubMed ID: 8938914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment.
    Szulc A; Galinska B; Tarasow E; Waszkiewicz N; Konarzewska B; Poplawska R; Bibulowicz D; Simonienko K; Walecki J
    Pharmacopsychiatry; 2011 Jun; 44(4):148-57. PubMed ID: 21710405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS.
    Théberge J; Al-Semaan Y; Williamson PC; Menon RS; Neufeld RW; Rajakumar N; Schaefer B; Densmore M; Drost DJ
    Am J Psychiatry; 2003 Dec; 160(12):2231-3. PubMed ID: 14638596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.
    Öngür D; Jensen JE; Prescot AP; Stork C; Lundy M; Cohen BM; Renshaw PF
    Biol Psychiatry; 2008 Oct; 64(8):718-726. PubMed ID: 18602089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combined diffusion tensor imaging and magnetic resonance spectroscopy study of patients with schizophrenia.
    Reid MA; White DM; Kraguljac NV; Lahti AC
    Schizophr Res; 2016 Feb; 170(2-3):341-50. PubMed ID: 26718333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.